Trial-by-gene · IDH1 / IDH2
Active clinical trials enrolling IDH1 / IDH2-mutant AML
Decision-support aid only — eligibility decisions must be confirmed against the actual trial protocol and the patient's medical record. Trial counts and statuses change daily; this page is for orientation, not adjudication.
IDH-mutant AML trials focus on (1) ivosidenib + venetoclax + azacitidine triplets and other combinations to extend response durability, (2) post-IDHi resistance (isoform switching, second-site mutations), (3) MRD-driven maintenance strategies, and (4) IDH inhibitors in higher-risk MDS pre-progression.
See the IDH1/2 AML cheat sheet.
Browse the live listing
Search ClinicalTrials.gov for actively recruiting AML trials with IDH-directed interventions.
Open ClinicalTrials.gov listingSource: ClinicalTrials.gov, US National Library of Medicine. Trial-listing data is in the public domain. Use of ClinicalTrials.gov data must comply with the NLM terms of use.
Representative trial phases and designs
Phase III, 1L
Ivosidenib + venetoclax + azacitidine vs venetoclax + azacitidine in newly diagnosed IDH1-mutant AML (low-intensity).
Phase II, post-IDHi
Olutasidenib after ivosidenib; combination strategies after first-line IDHi resistance.
Phase I/II, IDH-mutant MDS
Ivosidenib or enasidenib in higher-risk MDS pre-progression.
Frequently asked questions
- Are post-IDHi resistance trials open to both IDH1 and IDH2?
- Many are designed for specific isoforms; check the inclusion criteria. Some combination trials accept either.